2023 Right Heart Symposium
Full Details can be found at: https://thrombosis.org/events/2023-right-heart-symposium/
Pulmonary vascular disease (PVD), including pre- and post-capillary pulmonary hypertension, are a spectrum of progressive, symptomatic, and ultimately fatal disorders for which significant advances in treatment have been made. Despite advances in the management of PVD, the mortality rate remains disproportionate. Evaluation and treatment are often delayed until patients present with serious complications. Effective management requires timely recognition, accurate diagnosis, and selection of the different therapeutic options.
Progression to right ventricular dysfunction and finally failure can occur as an acute event in consequences where the pulmonary hypertension develops acutely as with pulmonary embolism, or because of a chronic condition such as pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD), interstitial lung disease, or chronic left sided heart or valvular disease.
Early detection and appropriate management can improve quality of life and may improve survival. Medical therapy has come a long way towards decreasing symptoms, enhancing performance, and improving prognosis, but there is still a long way to go, especially for the broader population of patients with PVD.
This program is tailored to clinical and research professionals who study and/or care for patients with right heart disease, congenital heart disease, pulmonary hypertension, and associated disorders.
At the end of this program, participants should be able to:
- Review the options for advanced imaging approaches to assess and monitor RV function and pulmonary vascular remodeling
- Describe pharmacologic interventions to augment or restore RV function in the patient with advanced PVD or critical illness
- Assess the latest interventional, device, and pharmacologic approaches to PVD and evaluate these options in various forms of PVD, including disease-modifying pathways such as PDGF and TGF-beta signaling
- Discuss advanced hemodynamic and physiologic correlates of right ventricular-pulmonary arterial coupling
This meeting will also offer an online option.
Charlie Lee, MPAS, MMS, PA-C
Stephanie Perella, PA-C
Aaron Waxman, MD, PhD
Associate Professor of Medicine, Harvard Medical School
Brigham and Women’s Hospital
Executive Director Center of Pulmonary Heart Diseases, Brigham and Women's Hospital
Deborah Whalen, RNP, MSN, MBA
Associate Director for Quality and Patient Safety, Department of Medicine
Assistant Professor of Medicine Chobanian and Avedisian School of Medicine
Program Manager: Claire Grimble, CMP
Credit Types: AMA, ANCC, AAPA, Participation
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and North American Thrombosis Forum. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Contact Hours: 12.75 of which 2.25 are eligible for pharmacology credit
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 12.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 12.50 AAPA Category I CME
- 12.50 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 12.75 ANCC
- 2.25 ANCC Pharmacology
- 12.50 Participation
United Therapeutics Corporation
Pharmosa Biopharm Inc.